Note: Descriptions are shown in the official language in which they were submitted.
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
Peptides and Peptide Derivatives as well as Pharmaceutical Compositions
containing the
same
The present invention relates to peptides and peptide derivatives, to the
production thereof as
well as to their use for preparing a therapeutically and/or preventively
active drug and to such
a pharmaceutical drug.
EP1586586 describes the use of peptides from the sequence of fibrin possessing
anti-
inflammatory effects.
Said effect may be based on the fact that the fibrin and fibrin fragments
generated during the
breakdown thereof bind to endothelial cells via its neo-N-terminus of the
Bbeta-chain and to
cells in the bloodstream via the sequence of the Aalpha-chain, thereby leading
to the adhesion
and transinigration of these cells into the tissue. The binding partner of the
fibrin and fibrin
fragments to the endothelial cells is the protein vascular endothelial (VE)
cadherin, which is
expressed exclusively in the adherens junction between neighboring endothelial
cells. The
peptides according to the invention block this interaction and thereby
counteract the
transmigration of blood cells. The natural defense against infections by the
leukocytes in the
blood is not adversely effected, however. Thus, the composition of the sarne,
such as
granulocytes, lymphocytes and monocytes, remains unaffected so that the
natural defense
process is maintained.
Fibrinogen is produced in the liver and, in this form, is biologically
inactive and normally is
provided in the blood at concentrations of around 3 g/1. Proteolytic cleavage
of the proenzyme
prothrombin results in the formation of thrombin, which cleaves off the
fibrinopeptides A and
B from the fibrinogen. In this way, fibrinogen is transformed into its
biologically active form.
Fibrin and fibrin cleavage products are generated.
Thrombin is formed whenever blood coagulation is activated, i.e. with damage
to the tissue,
be it of inflammatory, traumatic or degenerative genesis. The formation of
fibrin as mediated
by thrombin is basically a protective process aimed at quickly sealing any
defects caused to
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
2
the vascular system. However, the formation of fibrin also is a pathogenic
process. The
appearance of a fibrin thrombus as the triggering cause of cardiac infarction
is one of the most
prominent probleins in human medicine.
The role which fibrin plays during the extravasation of inflammatory cells
from the
bloodstream into the tissue, which, on the one hand, is a desired process for
the defense
against pathogenic microorganisms or tumor cells in the tissue, but, on the
other hand, is a
process which, by itself, induces or prolongs damage done to the tissue, has
so far not been
examined at all or not to a sufficient extent. Fibrin binds to endothelial
cells via its neo-N-
terminus of Bbeta by means of the sequence to Bbeta and to cells in the
bloodstream by
means of the sequence Aalpha, thereby leading to the adhesion and
transmigration of cells
into the tissue.
By way of the mechanism described above the peptides or proteins according to
the invention
may prevent the adhesion of cells from the bloodstream to endothelial cells of
the vascular
wall and/or their subsequent transmigration from the blood into the tissue.
W09216221 describes polypeptides which are covalently linked to long-chain
polymers, as
for instance methoxy-polyethylene glycol (PEG). The binding of polypeptides to
such
polymers frequently results in a prolongation of the biological half-life of
these polypeptides
and delays their renal excretion. A summary of these properties may be found
in Davis et al.,
Polymeric Materials Pharmaceuticals for Biomedical Use, pp. 441-451 (1980) The
addition of
PEG-groups exerts this effect in a way proportional to the molecular weight of
the PEGylated
peptide, as, up to a certain size of the molecule, the glomular filtration
rate is inversely
proportional to the molecular weight.
W02004/101600 also describes new poly(ethylene glycol)-modified compounds and
their
use, in particular with emphasis on modified peptides activating the
erythropoietin receptor.
Further examples for the covalent modification of peptides and proteins PEG
residues are
interleukins (Knauf et al., J. Biol Chem. 1988, 263, 15064; Tsutumi et al., J.
Controlled
Release 1995, 33, 447), Interferons (Kita et al., Drug Delivery Res. 1990, 6
157), Catalase
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
3
(Abuchowski et al., J. Biol. Chem. 1997, 252, 3582). A review of the prior art
may be found
in Reddy, Ann. of Pharmacotherapy, 2000, 34, 915.
A prolonged biological half-life is advantageous for various therapeutic uses
of peptides. This
is in particular true in cases of chronic diseases where the administration of
the active agent
over a prolonged period of tiine is indicated. With such indications this may
improve the
patient's compliance, as applying the active agent once a day will for
instance be accepted
more easily than continuous infusion. Apart from increasing the molecular mass
by covalent
modification, a prolongation of the persistency of polypeptides may be
obtained by modifying
them in such a way that their degradation by proteolytic enzymes (e.g. exo- or
endoproteases
or peptidases) is prevented.
Using various examples it has been shown that it is necessary to customize the
appropriate
modification for each peptide so as to prevent a significant influence on the
pharmacodynamic effect as compared to the unmodified peptide. In this context
the following
may be referred to: Calcitonin (Lee et al. Pharm. Res. 1999, 16, 813), Growth
Hormone
Releasing Hormone (Esposito et al., Advanced Drug Delivery Reviews, 2003, 55,
1279),
Glucagon like peptide 1(Lee et al., Bioconjugate Res. 2005, 16, 377), as well
as the growth
hormone-receptor antagonist Pegvisomant (Ross et al., J. Clin. Endocrin.
Metab. 2001, 86,
1716). The reviews by Caliceti and Veronese (Adv. Drug Deliv. Rev. 2003, 55
1261) and by
Harris and Chess (Nature Rev. Drug Discovery 2003, 2, 214) discuss that in
case of designing
peptide- or protein-PEG-conjugates it is necessary to take into consideration
the structure of
the original substance, the molecular weight of the peptide and the polymer,
the number of
conjugated polymer chains as well as the linker chemistry, so as to obtain an
effective
peptide-PEG-conj ugate.
Surprisingly it has now been found that peptides derived from the chain of the
Bbeta(15-42)fibrin fragment, wherein one or several amino acids of the natural
fibrin
sequence have been substituted by other amino acids, as well as derivatives
modified at the C-
terminal end of the peptide sequence also have strong anti-inflammatory
effects. The same
applies to peptides and peptide derivatives the modification of which prevents
their
destruction by proteases or peptidases, as well as to peptide-PEG-conjugates
derived from the
basic sequence of the Bbeta(15-42)fibrin fragment.
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
4
Thus the invention relates to modified peptides which are derived from the
chain of the
Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of
the sequence
have been substituted by genetically encoded or not genetically encoded amino
acids or
peptidomimetics.They may exist as free peptides or as C-terminal derivative
and/or being
linked to a polyethylene glycol (PEG)-polymer, and have anti-inflammatory
and/or
endothelium stabilizing effects. Esters or amides may for instance be taken
into consideration
as C-terminal derivatives.
The inventive compounds may have conservative substitutions of amino acids as
compared to
the natural sequence of fibrin of the warm blooded animals to be treated in
one or several
positions. A conservative substitution is defined as the side chain of the
respective amino acid
being replaced by a side chain of similar chemical structure and polarity, the
side chain being
derived from a genetically coded or not genetically coded amino acid. Families
of amino
acids of this kind having similar side chains are known in the art. They
comprise for instance
amino acids having basic side chains (lysins, arginins, histidine), acidic
side chains (aspartic
acid, glutamic acid), uncharged polar side chains (glycine, aspartamic acid,
glutamine, serine,
threonine, tyrosine, cysteine), non-polar side chains (alanine, valine,
leucine, isoleucine,
proline, phenylalanine, methionine, tryptophan), beta-branched side chains
(threonine, valine,
isoleucine) and aromatic side chains (tyrosine, phenylalanine, tryptophane,
histidine). Such
conservative substitutions of side chains may preferably be carried out in non-
essential
positions. In this context, an essential position in the sequence is one
wherein the side chain of
the relevant amino acid is of significance for its biological effect.
The invention in particular concerns peptides and peptide derivatives of the
following general
formula I:
H2N-GHRPX1X2X3X4X5X6X7X8PX9X10X1 iPXi2PPPX13X14XISX16GYR-Xl7 (1),
wherein:
X1- X16 denote one of the 20 genetically encoded amino acids,
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
X17 denotes ORl with Rl = hydrogen or (C1- Cio )- alkyl, or
NR2R3, R2 and R3 being identical or different and denoting hydrogen,
(C1- Clo) - alkyl, or a residue -PEG5-60x , wherein the PEG-residue is linked
to
the N atom via a spacer, or
a residue NH-Y-Z-PEG5-60x, wherein Y denotes a chemical bond or a
genetically coded amino acid from among the group of S, C, K or R, and
Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may
be linked, as well as the physiologically acceptable salts thereof,
or wherein
X15 or X16 denote an arnino acid from the group of C or K, which is linked to
a
residue Z-PEGs-60x via the heteroatom in the side chain, and wherein
X17 denotes ORI, with Ri = hydrogen or (C1- Clo )- alkyl, or
NR2R3, RZ and R3 being identical or different and denoting hydrogen or
(Ci - Cio) - alkyl,
as well as the physiologically acceptable salts thereof.
A preferred subject matter of the invention are peptides and peptide
derivatives of the general
Formula I, wherein:
XI, X9, Xlo, X14 denote L, I, S, M or A,
X2, X6, X7 denote E or D,
X3, X4, XS, Xl l denote R or K
Xs, X12 denote A, G, S, or L
X13 denotes I, L or V and wherein
Xrs, X16 and X17 have the sarne meaning as given above,
as well as the physiologically acceptable salts thhereo
A particularly prefeiTed subject matter of the invention are peptides and
peptide derivates of
Formula II,
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
6
H2N-GHRPLDKKREEAPSLRPAPPPISGGGYR- X17 (II),
wherein XI7 has the same meaning as given above for Formula I, as well as the
physiologically acceptable salts thereof.
A most highly preferred subject matter of the present invention are compounds
of Formula
(II), wherein
XI7 denotes NR2R3, R2 and R3 being identical or different and being
hydrogen or (C1- Clo)- alkyl, or a residue
C(NRZR3) -(S-succinimido)-(PEGS-40K), the succinimide residue being
linked via C-atom 3 to the sulfur atom of the cysteine residue.
as well as the physiologically acceptable salts thereof.
A furthermore most highly preferred subject matter of the invention are
peptide derivatives of
Formula (III),
H2N-GHRPLDKKREEAPSLRPAPPPIS-X19-X20- X21-YR-XI7 (III)
wherein two of the residues X19, XZO and X21 each are a glycine residue and
the remaining one
is a residue C-(S-succinimido)-(PEG5-40x ), the succinimido residue being
linked to the sulfur
atom of the cysteine residue via C-atom 3,
and wherein X17 denotes NR2R3, RZ and R3 being identical or different and
being hydrogen or
(Ci - Clo) - alkyl,
as well as the physiologically acceptable salts thereof.
A furthermore most highly preferred subject matter of the invention are
peptide derivatives of
Formula (III),
HZN-GHRPLDKKREEAPSLRPAPPPIS-X19-XZO- X21-YR-X17 (III)
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
7
wherein two of the residues X19, X20 and X21 each are a glycine residue and
the remaining one
is a residue K- (PEG5-40x), the PEG-residue being linked via the nitrogen atom
in the side
chain of the lysine residue, and wherein
X17 denotes NR2R3, R2 and R3 being identical or different and being hydrogen
or (C1- C10) -
alkyl, as well as the physiologically acceptable salts thereof.
In the above formulas I and II the following letters represent amino acid
residues in
accordance with the general annotation for proteins and peptides:
pPhenylalanine is F, leucine
is L, isoleucine is 1, methionine is M, valine is V, serine is S, proline is
P, threonine is T,
alanine is A, tyrosine is Y, histidine is H, glutamine is Q, asparagine is N,
lysine is K, aspartic
acid is D, glutamic acid is E, cysteine is C, tryptophan is W, arginine is R,
glycine is G.
The amino acid residues in the compounds of Formula I may either be present in
their p or
their L configuration.
The terin peptide refers to a polymer of these amino acids, which are linlced
via an amide
linkage.
"Physiologically acceptable" means that salts are formed with acids or bases
the addition of
which does not have undesirable effects when used for humans. Preferable are
salts with acids
or bases the use of which is listed for use with warm blooded animals, in
particular humans,
in the US Pharmacopoeia or any other generally recognized pharmacopoeia.
PEG stands for a polyethylene glycol residue having a molecular weight of
between 5.000
and 60.000 Dalton, this molecular weight being the maximum of a molecular
weight
distribution, so that individual components of the mixture may have a higher
or lower
molecular weight.
The invention fiuthermore concerns processes for the production of the
peptides and peptide
derivatives of general Formula (1), characterized in that, either
(A) the first amino acid at the C-terminal end of the respective sequence is
linked to a
polymeric resin via a suitable cleavable spacer, the subsequent amino acids,
optionally
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
8
containing suitable protective groups for functional groups, are linked step
by step
according to methods known in the art, the finished peptide is cleaved off the
polymeric resin according to suitable methods known in the art, the protective
groups,
if present, are cleaved off by suitable methods and the peptide or peptide
derivative is
purified according to suitable methods, or
(B) a PEG-group having a desired molecular weight is linked to a polymeric
resin via a
suitable spacer, the first amino acid at the N-terminal end of the peptide is
linked
using suitable methods, the remaining steps being the same as described in
(A), or
(C) a lysine residue, containing a suitable protective group at the -amino
group is linked
to a suitable polymeric resin via a suitable spacer using suitable methods,
the peptide
chain is synthesized as described in (A), following cleavage from the
polymeric resin
and purification, if necessary, the protective group at the s-amino group is
cleaved off
using suitable methods, a PEG group having a desired molecular weight is
linked to
the s-amino group using a suitable activated reagent, the optionally remaining
protective groups are cleaved off and the final product is purified using
suitable
methods, or
(D) a peptide containing a cysteine residue is reacted with a PEG-maleimide to
form
compounds of Formula (III).
Suitable processing steps following (A), (B) or (C) as well as suitable
reagents are for
instance described in document WO 2004/101600.
Embodiinents of the respective processing steps are not new per se and will be
clear to an
experienced specialist in the field of organic synthesis.
Processes for linking a PEG-residue to a peptide chain will be known to the
skilled artisan.
For instance, a cysteine (C)-residue may be reacted with PEG-maleimide,
resulting in a
succinimide residue as spacer for residue Z. A further possibility is reacting
an optionally
activated C-terminal carboxy residue with an aminoalkyl-substituted PEG
residue. A further
possibility is the introduction of a PEG residue by reacting an aldehyde-
substituted PEG
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
9
residue with the s-amino function of a lysine residue. Activated PEG reagents
having suitable
spacers and reactive groups may for instance be obtained from NOF Corporation
(Tokyo,
Japan).
The substances according to the invention and the use of the substances
according to the
invention for the production of a pharmaceutical drug are of particular
significance for the
production of a pharmaceutical drug for the therapy of diseases resulting from
the tissue-
damaging effect of white blood cells, or wherein the integrity and full
physiological integrity
of the layer of endothelial cells lining the blood vessels is impaired.
Diseases belonging to this group are those in context with autoimmunity, as
for instance
collagenoses, rheumatic diseases, inflammatory bowel diseases like Morbus
Crohn or Colitis
ulcerosa, psoriasis and psoriatic rheumatoid artbritis, and
post/parainfectious diseases as well
as diseases caused by a graft-versus-host reaction. A healing effect takes
place as this medical
drug blocks the migration of the white blood cells into the tissue. Thus the
white blood cells
remain in the blood stream and cannot cause an autoreactive effect harmful to
the tissue. This
effect of the inventive substances is fiirthermore important for the treatment
of shock
conditions, in particular in case of septic shock triggered by infection with
gram-positive or
gram-negative bacterial pathogens as well as viral infections and haemorrhagic
shock caused
by heavy loss of blood because of severe injuries or bacterial or viral
infections.
The inventive substances may generally be used in situations that can be
described with the
terms "Systemic Inflammatory Response Syndrome (SIRS)", "Acute Respiratory
Distress
Syndrome (ARDS)" and organ- or multiorgan failure, respectively.
With a pharmaceutical drug for the therapy and/or prevention of rejection
reactions of organ
transplants there is a healing effect as this pharmaceutical drug prevents the
migration of
white blood cells from the blood stream into the donor organ, and the donor
organ can
therefore not be destroyed for instance by autoreactive lymphocytes.
With a pharmaceutical drug for the therapy and/or prevention of
arteriosclerosis there is a
healing and/or preventive effect as this pharmaceutical drug blocks the
migration of
lymphocytes and inonocytes into the wall of the tissue and thus the activation
of the cells of
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
the tissue wall. Thus the progress of arteriosclerosis is minimized or
stopped, the
progredience of arteriosclerotic plaque resulting therefrom is inhibited,
causing the
arteriosclerosis to recede.
With a pharmaceutical drug for the therapy and/or prevention of reperfusion
trauma following
surgically or pharmaceutically induced re-supply with blood, e.g. following
percutaneous
coronary intervention, stroke, vessel surgery, cardiac bypass surgery and
organ transplants,
there is a healing and/or preventive effect as this pharmaceutical drug
inhibits the migration of
lymphocytes, neutrophils and monocytes into the wall of the vessel.
Reperfusion trauma is
caused by a lack of oxygen/acidosis of the cells of the vessel during its re-
supply with blood,
leading to their activation and/or damage. Because of this, lymphocytes,
neutrophils and
monocytes adhere to the vessel wall and migrate into it. Blocking the
adherence and
migration of lymphocytes, neutrophils and monocytes in the vessel wall causes
the
hypoxy/acidosis-induced damage to abate, without the subsequent inflammatory
reaction
causing a permanent damage to the vessel. The endothelium-stabilizing effect
of the inventive
compounds f-urthermore prevents the formation of oedemas as well as any
further damage to
the organs supplied via the respective blood vessels.
With a pharmaceutical drug for the therapy and/or prevention of
arteriosclerosis as a
consequence of inetabolic diseases or the process of aging, there is a healing
and/or
preventive effect as this pharmaceutical drug inhibits the migration of
lymphocytes,
neutrophils and monocytes into the vessel wall, thus inhibiting the
progredience of
arteriosclerotic plaque resulting thereform.
The pharmaceutical drug according to the invention may also be used for the
transporta.tion of
another drug. The inventive drug specifically binds a surface molecule on
endothelial cells.
Thus drugs linked thereto may be delivered to endothelial cells in high
concentrations without
any danger of them having side effects at other sites. An example that may be
cited here is the
use of substances inhibiting the division of cells, which, specifically
brought to endothelial
cells, may have an antiangiogenetic effect. This brings about a healing effect
in tumor
patients, as tiunor growth is blocked by preventing the proliferation of
endothelial cells and
thus by preventing neoangiogenesis. The inventive compounds theinselves may
also develop
an antiangiogenetic effect, as they, because of their endothelium-stabilizing
effect, prevent the
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
11
endothelial cells from changing into a proliferative phenotype and thus
prevent the formation
of new capillary blood vessels. Therefore they are themselves suitable for the
treatment of all
kinds of tumor diseases as well as the prevention and/or treatment of tumor
metastases.
The inventive compounds of Formula (I) together with pharmaceutical adjuvants
and
additives, may be formulated into pharmaceutical preparations which also are a
subject matter
of the present invention. In order to prepare such formulations a
therapeutically effective dose
of the peptide or peptide derivative is mixed with pharmaceutically acceptable
diluents,
stabilizers, solubilizers, emulsifying aids, adjuvants or carriers and brought
into a suitable
therapeutic form. Such preparations for instance contain a dilution of various
buffers (e.g.
Tris-HCI, acetate, phosphate) of different pH and ionic strength, detergents
and solubilizers
(e.g. Tween 80, Polysorbat 80), antioxidants (e.g. ascorbic acid), and fillers
(e.g. lactose,
mannitol). These formulations may influence the biological availability and
the metabolic
behavior of the active agents.
The pharmaceutical preparations according to the invention may be
adrninistered orally,
parenterally (intramuscularly, intraperitoneally, intravenously or
subcutaneously),
transdermally or in an erodable implant of a suitable biologically degradable
polymer (e.g. .
polylactate or polyglycolate).
The biological effect and applicability for the claimed use of the inventive
compounds may
for instance be determined in an assay in which a culture of human umbilical
cord endothelial
cells is examined microscopically after stimulation with the õN-terminal
disulfide knot
protein II" (NDSK-II) or with thrombin. The stimulation of endothelial cells
causes the
formation of gaps between the cells in a densely packed cell layer. Treatment
with the
inventive compounds may prevent the formation of these gaps, and is successful
in closing
gaps that have already been forzned. This effect is predicative for the
protective effect on the
endothelium the inventive compounds have throughout the organism. The
inventive
compounds have an effect in the range of concentrations from 0.01 nM to 1 mM,
preferably in
the range from 1 nM to 0.1 mM in the bath solution of cells.
The effectiveness in vivo inay for instance be established using a model of
acute pulmonitis in
a rodent. For this the treatment of the animal and the administration of the
substance are
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
12
carried out as described in Exasnple 7 below. The inventive coinpounds show an
effect at a
dose ranging fiom 0.001 mg/kg body weight to 500 mg/kg body weight, preferably
at a dose
ranging from 0.1 mg/kg to 50 mg/kg.
A further possibility for establishing the biological effect in vivo is the
reduction or complete
suppression of mortality because of an infection with haemolytic viruses or
bacteria. For this
purpose, mice are, as described in Example 8, for instance infected with a
dose of Dengue
viruses, wherein 50% of the animals die within a period of 5-20 days after
infection. The
inventive compounds bring about a reduction of this mortality at a dose
ranging from 0.001 to
500 mg/kg body weight, preferably at a dose ranging from 0.1 to 50 mg/g body
weight.
The following examples serve to illustrate the invention without limiting it
to the examples.
General Preparation and Purification of Peptides According to the Invention
The preparation and purification of the above peptide derivatives generally
takes place by way
of FMOC-strategy on acid-labile resin supports using a commercially available
batch peptide
synthesizer as also described in the literature (e.g. "solid phase peptide
synthesis - A practical
approach" by E. Atherton, R.C. Sheppard, Oxford University press 1989). N-
alpha-FMOC-
protected derivatives, the functional side-chains of which are protected by
acid-sensitive
protective groups, are used as amino acid components. Unless otherwise stated,
purification is
carried out by means of RP-chromatography using a water/acetonitrile gradient
and 0.1%
TFA as ion pair reagent.
Examnle 1
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile- S er-Gly-Gly-Gly-Tyr-Arg-NH2
100 mg Tentagel-S-RAM (Rapp-Polymere) at a load of 0.24 mmol/g are transferred
to a
commercially available peptide synthesis device (PSMM(Shimadzu)), wherein the
peptide
sequence is constructed step-by-step according to the carbodiimide/HOBt
method.
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
13
The FMOC-amino acid derivatives are pre-activated by adding a 5-fold equimolar
excess of
di-isopropy-carbodiimide (DIC), di-isopropy-ethylamine (DIPEA) und
hydroxybenzotriazole
(HOBt) and, following their transfer into the reaction vessel, mixed with the
resin support for
30 minutes. Washing steps are carried out by 5 additions of 900 l DMF and
thorough mixing
for 1 minute. Cleavage steps are carried out by the addition of 3 x 900 l 30%
piperidine in
DMF and thorough mixing for 4 minutes.
Removal of the individual reaction and wash solutions is effected by forcing
the solutions
through the bottom frit of the reaction vessel.
The amino acid derivatives FMOC-Ala, FMOC-Arg(Pbf),, FMOC-Asp, FMOC-Gly, FMOC-
His(Trt), FMOC-Ile, FMOC-Leu, FMOC-Lys(BOC), FMOC-Pro, FMOC-Ser(tBu) and
FMOC-Tyr(tBu) (Orpegen) are employed.
When synthesis is completed the peptide resin is dried. The peptide amide is
subsequently
cleaved off by treatment with trifluoracetic acid/TIS/ EDT/water (95:2:2:1
vol) for 2 hours at
room temperature. By way of filtration, concentration of the solution and
precipitation by the
addition of ice-cold diethyl ether the crude product (75 mg) is obtained as a
solid.
The peptide is purified by RP-HPLC on Kromasil RP-18 250-20, 10 m in 0.1% TFA
with a
gradient of 5 on 60% acetonitrile in 40 minutes at a flow rate of 12 ml/min
and evaluation of
the eluate by means of a UV detector at 215 nm. The purity of the individual
fractions is
determined by analyt. RP-HPLC and mass spectrometry. Following combination of
the
purified fractions and lyophilisation 48 mg of pure product are obtained Maldi-
TOF, 3036.6
m/z (m.i.).
Example 2
Gly-His-Arg-Pro-L eu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Cys-(S -succinimide-PEG20K)-OH
The monomeric peptide is synthesized as in Example l, Tentagel (Rapp Polymere)
being used
as resin support here with FMOC-Cys(Trt) as the first amino acid.
After cleavage and purification of the peptide reaction is carried out with a
2- to 8-fold molar
excess of maleinimido-PEG20K. Following recovery purification is carried out
on Kromasil
RP-18, and the identity of the product is confirmed by way of analytical RP-
HPLC and
MALDI-MS.
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
14
Example 3
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEG20K)-amide
100 mg Tentagel-S-RAM (Rapp-Polymere) at a load of 0.24 mmol/g are transferred
to a
commercially available peptide synthesis device (PSMM(Shimadzu)), wlherein the
peptide
sequence is constructed step-by-step according to the carbodiimide/HOBt
method.
The FMOC-amino acid derivatives are pre-activated by adding a 5-fold equimolar
excess of
di-isopropy-carbodiimide (DIC), di-isopropy-ethylamine (DIPEA) und
hydroxybenzotriazole
(HOBt) and, following their transfer into the reaction vessel, mixed with the
resin support for
30 minutes. Washing steps are carried out by 5 additions of 900 l DMF and
thorough mixing
for 1 minute. Cleavage steps are carried out by the addition of 3 x 900 l 30%
piperidine in
DMF and thorough mixing for 4 minutes.
Removal of the individual reaction and wash solutions is effected by forcing
the solutions
through the bottom frit of the reaction vessel.
The amino acid derivatives FMOC-Ala, FMOC-Arg(Pbf),, FMOC-Asp, FMOC-Gly, FMOC-
His(Trt), FMOC-Ile, FMOC-Leu, FMOC-Lys(BOC), FMOC-Pro, FMOC-Ser(tBu), FMOC-
Cys(Trt) and FMOC-Tyr(tBu) (Orpegen) are employed.
After cleavage and purification of the peptide reaction is carried out with a
2- to 8-fold molar
excess of maleinimido-PEG20K. Following recovery purification is carried out
on Kromasil
RP-18, and the identity of the product is confirmed by way of analytical RP-
HPLC and
MALDI-MS.
Example 4
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Cys-(S-succinimido-PEGaOx)-Gly-Tyr-Arg-amide
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
100 mg Tentagel-S-RAM (Rapp-Polymere) having a charge of 0.24 mmol/g are
transferred to
a commercially available peptide synthesis device (PSMM(Shimadzu)), wherein
the peptide
sequence is constructed step-by-step according to the carbodiimide/HOBt
method.
The FMOC-amino acid derivatives are pre-activated by adding a 5-fold equimolar
excess of
di-isopropy-carbodiimide (DIC), di-isopropy-ethylamine (DIPEA) und
hydroxybenzotriazole
(HOBt) and, following their transfer into the reaction vessel, mixed with the
resin support for
30 minutes. Washing steps are carried out by 5 additions of 900 l DMF and
thorough mixing
for 1 minute. Cleavage steps are carried out by the addition of 3 x 900 130%
piperidine in
DMF and thorough mixing for 4 minutes.
Removal of the individual reaction and wash solutions is effected by forcing
the solutions
through the bottom frit of the reaction vessel.
The amino acid derivatives FMOC-Ala, FMOC-Arg(Pbf),, FMOC-Asp, FMOC-Gly, FMOC-
His(Trt), FMOC-Ile, FMOC-Leu, FMOC-Lys(BOC), FMOC-Pro, FMOC-Ser(tBu), FMOC-
Cys(Trt) and FMOC-Tyr(tBu) (Orpegen) are employed.
When synthesis is completed the peptide resin is dried. The peptide amide is
subsequently
cleaved by treatment with trifluoracetic acid/TIS/ EDT/water (95:2:2:1 vol)
for 2 hours at
room temperature. By way of filtration, concentration of the solution and
precipitation by the
addition of ice-cold diethyl ether the crude product (75 mg) is obtained as a
solid.
The peptide is purified by RP-HPLC on Kromasil RP-18 250-20. The peptide thus
obtained is
reacted with maleinimido-PEG20k. Following recovery, purification by means of
gel
chromatography and lyophilisation a pure product is obtained, the identity of
which is
confirmed by way of RP-HPLC and MALDI-MS.
Example 5
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Cys-(S-succinimido-PEG20K)-Gly-Gly-Tyr-Arg-amide
Is obtained as in Example 4, the sequence of protected amino acids being
appropriately
altered.
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
16
Example 6
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Cys-(S-succinimido-PEGZOK)-Tyr-Arg-amide
Is obtained as in Example 4, the sequence of protected amino acids being
appropriately
altered.
The following were prepared as in Example 1:
Gly-His-Arg-Pro-Ile-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-Pro-
Il e-S er-Gly-Gly-Gly-Tyr-Arg-NH2
Gly-His-Arg-Pro-Ala-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-Pro-
I le- S er-Gly-Gly-Gly-Tyr-Arg-NH2
Gly-His-Arg-Pro-Leu-Asp-Arg-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-NH2
Gly-His-Arg-Pro-Leu-Asp-Lys-Arg-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Il e-S er-Gly-Gly-Gly-Tyr-Arg-NH2
Gly-His-Arg-Pro-L eu-Asp-Lys-Lys-Arg-Asp-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile- S er-Gly-Gly-Gly-Tyr-Arg-NH2
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys -Arg-Glu-Asp-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-NH2
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Lys-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-Pro-
Ile-S er- Gly-Gly-Gly-Tyr-Arg-NH2
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Gly-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-NH2
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
17
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Leu-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-NH2
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Lys-Pro-Ala-Pro-
Pro-Pro-
Ile-S er-Gly- Gly-Gly-Tyr-Arg-NHa
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ala-Gly-Gly-Gly-Tyr-Arg-NH2
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys -Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ala-Ala-Gly-Gly-Tyr-Arg-NH2
Gly-His-Arg-Pro-Ile-Asp-Lys-Arg-Arg-Glu-Glu-Ala-Pro-Ser-Ile-Arg-Pro-Ala-Pro-
Pro-Pro-
Ile-Ala-Gly-Gly-Gly-Tyr-Arg-NH2
The following were prepared as in Example 2:
Gly-His-Arg-Pro-Ile-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-Pro-
Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEG20K)OH
Gly-His-Arg-Pro-L eu-Asp-Arg-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEGIOx)OH
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Asp-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEG20K)OH
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ala-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEG20K)OH
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ala-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ala-Gly-Gly-Gly-Tyr-Arg-Cys-(S -succinimido-PEG20K) OH
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
18
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succiniinido-PEG1oK)OH
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEG20x)OH
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-P ro-S er-Ile-Arg-Pro-Ala-Pro-
Pro-Pro-
Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEGZOK)OH
The following were prepared as in Example 3:
Gly-His-Arg-Pro-Ile-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-Pro-
Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S -succinimido-PEG20K)amide
Gly-His-Arg-Pro-Leu-Asp-Arg-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEGIOK)amide
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Asp-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEG20K)amide
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ala-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Cys- (S-succinimido-PEG20K)amide
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ala-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ala-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succiniinido-PEG20K)amide
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S -succinimido-PEG 1 ox)amide
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEG20K)amide
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
19
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys -Arg-Glu-Glu-Ala-Pro-S er-Ile-Arg-Pro-Ala-Pro-
Pro-Pro-
Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-succinimido-PEG20K)amide
Example 7
The biological effect of the compound of Example 1 was established in a model
of LPS-
induced pneumonitis. C57 Black mice were randomized in two groups of 6 animals
each and
treated as follows:
Group 1 received 100ng/kg LPS intranasally, immediately after the
administration of LPS the
mice received 4.8 mg/ kg of the agent of Example 1(dissolved in 100 1 NaCI)
i.p., a second
dose followed 60 min after the adininistration of LPS.
Group 2 received 100ng/kg LPS intranasally, immediately after the
administration of LPS the
mice received 100 1 NaCI i.p., 60 min after the LPS admininistration the mice
again received
100 1 NaCI i.p. 6 hours after the application of LPS all groups were submitted
to a
bronchioalveolar lavage and the lungs were removed. From the lavage liquids
the number of
neutrophils (PMN) was determined. This brought the following results:
60 p<0.05
~ 50
1
0 40 *
m-
Z 30
a 20
0
Control Examnle 1
Example 8
The biological effect of the compound of Example 3 was established in a model
of Dengue
virus infection in mice. 5-week-old male BALB/c mice were divided into 2
groups. All
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
animals were infected subcutaneously with a mouse-adapted Dengue virus (DEN-2,
strain
P23085 at a dose of 1-2 LD50. 15 mice received 0.1 ml of 0.8% saline as
intramuscular
injection (control). The treated animals received 4.8 mg/kg/day of the agent
of Example 3 as
an intramuscular injection (diluted in 0.1 ml of 0.8% saline) once a day for 5
days, starting on
day 3 after the virus infection.
At the end of the treatment period (day 10) the survival rates were compared.
The following results were obtained:
Mortality Percentage
Control 8/15 47%
Example 3 0/10 0% p<0.05
Example 9
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S-CH2-C O-NH-PEG20x)-OH
The synthesis of the monomeric peptide is carried analogically to Example 1,
Tentagel of
(Rapp Polymere) being used as resin support here with FMOC-Cys(Trt) as the
first amino
acid.
Following cleavage and purification of the peptide reaction is carried out
with a suitable
excess of Br- CH2-CO-NH-PEG20K. Following recovery purification is carried out
on
Kroinasil RP-18, and the identity of the product is confirmed by MALDI-MS.
Example 10
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Cys-(S-CH2-CO-NH-PEG20K)-amide
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
21
100 mg Tentagel-S-RAM (Rapp-Polymere) at a load of 0.24 mmol/g are transferred
to a
commercially available peptide synthesis device (PSMM(Shimadzu)), wherein the
peptide
sequence is constructed step-by-step according to the carbodiimide/HOBt
method.
The FMOC-ainino acid derivatives are pre-activated by adding a 5-fold
equimolar excess of
di-isopropy-carbodiimide (DIC), di-isopropy-ethylamine (DIPEA) und
hydroxybenzotriazole
(HOBt) and, following their transfer into the reaction vessel, mixed with the
resin support for
30 minutes. Washing steps are carried out by 5 additions of 900 l DMF and
thorough mixing
for 1 minute. Cleavage steps are carried out by the addition of 3 x 900 130%
piperidine in
DMF and thorough mixing for 4 minutes.
Removal of the individual reaction and wash solutions is effected by forcing
the solutions
through the bottom frit of the reaction vessel.
The amino acid derivatives FMOC-Ala, FMOC-Arg(Pbf),, FMOC-Asp, FMOC-Gly, FMOC-
His(Trt), FMOC-Ile, FMOC-Leu, FMOC-Lys(BOC), FMOC-Pro, FMOC-Ser(tBu), FMOC-
Cys(Trt) and FMOC-Tyr(tBu) (Orpegen) are employed.
Following cleavage and purification of the peptide reaction is carried out
with a suitable
excess of Br- CH2-CO-NH-PEG20K. Following recovery purification is carried out
on
Kromasil RP-18, and the identity of the product is confirmed by MALDI-MS.
Example 11
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Cys-(S-CH2-CO-NH-PEG20K)-Gly-Tyr-Arg-amide
100 mg Tentagel-S-RAM (Rapp-Polymere) at a charge of 0.24 mmol/g are
transferred to a
commercially available peptide synthesis device (PSMM(Shimadzu)), wherein the
peptide
sequence is constructed step-by-step according to the carbodiimide/HOBt
method.
The FMOC-amino acid derivatives are pre-activated by adding a 5-fold equimolar
excess of
di-isopropy-carbodiimide (DIC), di-isopropy-ethylainine (DIPEA) und
hydroxybenzotriazole
(HOBt) and, following their transfer into the reaction vessel, mixed with the
resin support for
30 minutes. Washing steps are carried out by 5 additions of 900 l DMF and
thorough mixing
for 1 minute. Cleavage steps are carried out by the addition of 3 x 900 l 30%
piperidine in
DMF and thorough mixing for 4 minutes.
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
22
Removal of the individual reaction and wash solutions is effected by forcing
the solutions
through the bottom frit of the reaction vessel.
The amino acid derivatives FMOC-Ala, FMOC-Arg(Pbf),, FMOC-Asp, FMOC-Gly, FMOC-
His(Trt), FMOC-Ile, FMOC-Leu, FMOC-Lys(BOC), FMOC-Pro, FMOC-Ser(tBu), FMOC-
Cys(Trt) and FMOC-Tyr(tBu) (Orpegen) are employed.
When synthesis is completed the peptide resin is dried. The peptide amide is
subsequently
cleaved by treatment with trifluoracetic acid/TIS/ EDT/water (95:2:2:1 vol)
for 2 hours at
room temperature. By way of filtration, concentration of the solution and
precipitation by the
addition of ice-cold diethyl ether the crude product (75 mg) is obtained as a
solid.
The peptide is purified by RP-HPLC on Kromasil RP-18 250-20. The peptide thus
obtained is
reacted with O-(iodoacetyl)-N-hydroxysuccinimide, followed by amino-ethyl-oxi-
PEG2ok .
After recovery, purification by means of gel chromatography and lyophilisation
a pure
product is obtained, the identity of which is confirmed by MALDI-MS.
Example 12
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile- S er-Gly-Cys-(S -CH2-C O-NH-PEG20K)-Gly-Tyr-Arg-amide
Is obtained as in Example 11, the sequence of protected amino acids being
appropriately
altered.
The following were produced as in Example 9:
Gly-His-Arg-Pro-Ile-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-Pro-
Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Cys-(S-CHz-CO-NH-PEG20K) OH
Gly-His-Arg-Pro-Leu-Asp-Arg-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Cys-(S-CH2-CO-NH-PEG1oK)OH
Gly-His-Arg-Pro -Leu-Asp-Lys-Lys-Arg-Glu-Asp-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys--(S-CH2-C O-NH-PEG20K)OH
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
23
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ala-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile- S er-Gly-Gly-Gly-Tyr-Arg-Cys--(S -CH2-C O-NH-PEGZOK) OH
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ala-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ala-Gly-Gly-Gly-Tyr-Arg-Cys--(S-CH2-C O-NH-PEG20K) OH
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys--(S-CH2-CO-NH-PEGIOK)OH
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys--(S -CH2-C O-NH-PEG20K) OH
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Ile-Arg-Pro-Ala-Pro-
Pro-Pro-
Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys--(S-CHZ-CO-NH-PEG20K)OH
The following were produced as in Example 10:
Gly-His-Arg-Pro-Ile-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-
Pro-Pro-
Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys-(S -CH2-CO-NH-PE G20K) amide
Gly-His-Arg-Pro-L eu-Asp-Arg-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Cys-(S-CHz-CO-NH-PEGI ox)amide
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Asp-Ala-Pro-S er-Leu-Arg=Pro-Ala-Pro-
Pro-
Pro-Ile- S er-Gly-Gly-Gly-Tyr-Arg-Cys--(S-CH2- CO-NH-PEGZOK)amide
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ala-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys--(S-CH2-CO-NH-PEG20K)amide
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ala-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ala-Gly-Gly-Gly-Tyr-Arg-Cys--(S-CH2-CO-NH-PEG20x)arnide
CA 02641908 2008-08-11
WO 2007/095660 PCT/AT2007/000095
24
Gly-His-Arg-P ro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Cys--(S-CHZ-CO-NH-PEGI oK)arnide
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-S er-Leu-Arg-Pro-Ala-Pro-
Pro-
Pro-Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys--(S-CH2-CO-NH-PEG20K)amide
Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Ile-Arg-Pro-Ala-Pro-
Pro-Pro-
Ile-S er-Gly-Gly-Gly-Tyr-Arg-Cys--(S-CHZ-C O-NH-PEG20K)amide
